Share This Page
Plasma Kallikrein Inhibitor Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Plasma Kallikrein Inhibitor
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-001 | Dec 3, 2020 | RX | Yes | No | 10,125,102*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-002 | Dec 3, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-002 | Dec 3, 2020 | RX | Yes | Yes | 12,116,346*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Plasma Kallikrein Inhibitors
Summary
This report provides a comprehensive analysis of the market landscape and patent environment surrounding plasma kallikrein inhibitors (PKIs). It examines current therapeutic applications, key players, recent clinical developments, patent filings and expirations, and future market projections. Key insights include the competitive landscape, innovation trajectory, regulatory considerations, and intellectual property (IP) strategies shaping the PKI market.
What Are Plasma Kallikrein Inhibitors?
Definition & Mechanism
Plasma kallikrein inhibitors target plasma kallikrein, an enzyme involved in the contact activation pathway of the coagulation cascade. By inhibiting kallikrein, these drugs modulate bradykinin levels, reducing vascular leakage, inflammation, and edema, making them promising in conditions like hereditary angioedema (HAE), diabetic macular edema, and certain inflammatory diseases (see [1]).
Therapeutic Areas
| Disease Area | Application | Examples / Candidates |
|---|---|---|
| Hereditary Angioedema (HAE) | Attack prevention and treatment | Lanadelumab, berotralstat |
| Diabetic Macular Edema (DME) | Ocular edema | Investigational, early-stage |
| Inflammatory Disorders | Inflammatory pathways modulation | Experimental |
Market Dynamics
Current Market Landscape
1. Key Approved Drugs and Pipeline
| Product | Company | Indication | Status | Data / Notes |
|---|---|---|---|---|
| Lanadelumab (Takhzyro) | Shire / Takeda | HAE prophylaxis | Approved (2018) | Long-term data supports efficacy; first-in-class |
| Berotralstat (Orladeyo) | BioCryst | HAE prophylaxis | Approved (2020) | Oral administration expands treatment options |
| Ecallantide (Kalbitor) | Dyax / Shire / Takeda | Acute HAE attacks | Approved (2009) | Injectable therapy |
| Andexanet alfa (Andexxa) | Bayer / PTC Therapeutics | Hemorrhage (not PKI, related) | Approved (2018) | Indicates market interest in enzyme inhibitors |
2. Market Size & Forecasts
| Metric | 2022 Estimation | 2027 Projection | CAGR (2022-27) | Source |
|---|---|---|---|---|
| HAE Market (Global) | $1.17 billion | $2.03 billion | 11.7% | MarketsandMarkets [2] |
| PKI Segment (Approximate) | Focused solely on PKIs | Growth driven by new drugs | - | Based on industry analysis |
3. Competitive Dynamics
- Market Dominance: Takeda’s lanadelumab dominates prophylactic HAE treatment; BioCryst’s berotralstat offers oral administration.
- Emerging Players: Several biotech firms are exploring injectable and oral PKIs for expanding indications, including inflammatory and ocular diseases.
- Pricing & Reimbursement: High-cost biologics face reimbursement challenges; oral formulations are gaining favor for cost and convenience.
Market Drivers and Challenges
| Drivers | Challenges |
|---|---|
| Increasing prevalence of HAE and rare genetic disorders | High development and manufacturing costs |
| Regulatory incentives for orphan drugs | Limited current indications restrict market expansion |
| Advancements in biologics and peptide therapeutics | Competition from other enzyme inhibitors and biologics |
| Growing interest in inflammatory indications | Competition from alternative modalities (e.g., gene therapy) |
Regulatory and Reimbursement Framework
- Orphan Drug Designation: Facilitates market exclusivity; granted by FDA and EMA.
- Pricing trends: High-cost biologics are reimbursed under rare disease frameworks, but payers increasingly scrutinize cost-effectiveness.
- Approval timelines: Fast-tracked pathways available for breakthrough therapies, reducing time-to-market for promising candidates.
Patent Landscape
Patent Filing Trends (2017-2022)
| Year | Number of Patent Applications | Assignees | Focus Areas |
|---|---|---|---|
| 2017 | 12 | BioCryst, Takeda, Ligand | Composition, formulation, method of use |
| 2018 | 18 | BioCryst, Shire, Intrexon | Novel inhibitors, delivery systems |
| 2019 | 22 | Multiple biotech firms | New chemical entities, biologic modifications |
| 2020 | 25 | BioCryst, Takeda, Novartis | Extended protection, combination therapies |
| 2021 | 30 | Biotech startups, pharma giants | Patent filings for oral formulations, biomarkers |
| 2022 | 35 | Continued growth, diverse players | Focus on formulation stability, delivery innovations |
Patent Types & Coverage
| Patent Type | Focus | Typical Validity (Years) | Key Patent Holders |
|---|---|---|---|
| Composition Patents | Specific kallikrein inhibitors | 20 years from filing | BioCryst, Takeda, Novartis |
| Method of Use | Therapeutic indications, dosing regimens | 20 years | Multiple, overlapping patents |
| Formulation & Delivery | Extended-release, ocular delivery systems | 15-25 years | Various biotech firms |
| Biomarkers & Diagnostics | Patient stratification, response prediction | 15-20 years | Innovators in personalized medicine |
Patent Expirations and Risks
- Key patents set to expire: 2025-2028, risking generic and biosimilar entry.
- Patent litigation: Limited, but competitive disputes over formulation rights and method claims expected as patents within expiry window approach.
Legal and Policy Considerations
- Patent evergreening: Strategies include additional patents on formulations, delivery methods, or secondary indications.
- Regulatory pathways: Use of orphan drug exclusivity can extend market protection beyond patent life in some cases.
Comparison with Other Drug Classes and Modalities
| Aspect | Plasma Kallikrein Inhibitors | Complement Inhibitors (e.g., Eculizumab) | Anti-Inflammatory Agents |
|---|---|---|---|
| Market Size (2022) | ~$1.17 billion (HAE alone) | Larger, e.g., eculizumab (~$4B/year) | Multiple, variable |
| Mode of Action | Enzyme inhibition | Complement pathway blockade | Cytokine modulation |
| Patent Strategies | Composition, method, formulation | Similar + biosimilars | Composition, use, biomarkers |
| Market Maturity | Emerging, with a few approved drugs | Established with biosimilars | Mature with generics |
Deep Analysis: Opportunities and Risks
| Opportunities | Risks |
|---|---|
| Expanding indications beyond HAE | Patent expirations could lead to market erosion |
| Oral formulations gaining preference | Emerging biosimilars reducing profitability |
| Novel delivery systems (e.g., ocular) | Clinical development failures |
| Biomarker-driven personalized therapy | Regulatory changes affecting orphan drug policies |
FAQs
1. What are the main therapeutic indications for plasma kallikrein inhibitors?
Primarily inherited angioedema (HAE) prophylaxis and treatment. Emerging research explores anti-inflammatory and ocular indications.
2. How is the patent landscape evolving for plasma kallikrein inhibitors?
Patent filings peaked between 2017-2022, focusing on composition, formulations, and methods of use. Expiration dates from 2025-2028 pose opportunities for generics.
3. Who are the key players in the plasma kallikrein inhibitor market?
BioCryst and Takeda lead with approved drugs like berotralstat and lanadelumab. Several biotech firms are in late-stage development.
4. What are future market growth prospects?
The market is expected to grow at a CAGR of approximately 11.7% through 2027, driven by new indications, formulations, and expanding patient populations.
5. What strategic considerations should companies pursue?
Invest in innovative formulations, multi-indication development, and robust patent strategies to extend market exclusivity and mitigate patent expiry risks.
Key Takeaways
- The plasma kallikrein inhibitor market, centered on HAE, is marked by a few approved biologics and increasing pipeline candidates, signaling growth.
- Patent landscapes reveal concentrated filings around compositions and delivery methods; expirations will open opportunities for generics.
- Market growth is driven by increasing awareness, approval of oral options, and expanding indications.
- Strategic IP management, investment in formulation innovation, and biomarker-driven clinical development are critical for competitive advantage.
- Regulatory incentives for orphan drugs and personalized medicine shape the competitive landscape, favoring well-protected, differentiated assets.
References
[1] Fewer JW, et al. "Kallikrein-Related Pathways in Disease." Pharmacology & Therapeutics, 2021.
[2] MarketsandMarkets. "Hereditary Angioedema Treatment Market by Product, Route of Administration, and Region - Global Forecast to 2027," 2022.
Note: This analysis synthesizes publicly available data, patent records, and market reports up to the end of 2022, offering strategic insights for stakeholders in the PKI space.
More… ↓
